Navigation Links
Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor

BOSTON, Jan. 13 /PRNewswire/ -- Johnston Blakely & Company, LLC, a Boston-based life science investment bank, is pleased to announce that Michael D. Webb has joined the firm as senior advisor. In this role, Mr. Webb will participate with the firm on internal and client-related activities including merger & acquisition advisory services and private equity placements, with a particular focus on biopharmaceutical transactions. "We are delighted to have someone of Mike's caliber join the Johnston Blakely team," said Johnston Blakely founder Benjamin Conway. "His extensive senior management experience and depth of sector knowledge will be of tremendous value to both the firm and its clients."

Mr. Webb was previously President & CEO of EPIX Pharmaceuticals where he completed over $225 million in financings, including its 1997 IPO, and raised an additional $150 million through corporate partnerships. Prior to EPIX, Mr. Webb was Senior Vice President, Worldwide Marketing and Strategic Planning for Ciba Diagnostics. Most recently he has been active with Ascent Therapeutics where as founder, president & CEO he organized the company and secured its initial $20 million in venture financing. Mr. Webb holds an M.B.A. with highest honors from Northwestern University's Kellogg Graduate School of Management.

About Johnston Blakely & Company

Johnston Blakely & Company, LLC is a Boston-based investment bank offering merger & acquisition-related financial advisory and private equity placement services to companies in the life science sector. The firm incorporates the venture capital tradition of comprehensive company involvement into investment banking engagements to deliver superior results for its clients. More than investment banking...inVenture banking(TM).

Johnston Blakely is a registered broker/dealer and member of FINRA/SIPC.

SOURCE Johnston Blakely & Company, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
2. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
3. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
4. Micromet Added to NASDAQ Biotechnology Index
5. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
6. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
7. Yongye Biotechnology Announces Record Third Quarter Results
8. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):